Authors’ Reply to Cattaneo et al.: “Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin6”

Detalles Bibliográficos
Autores principales: Cojutti, Pier Giorgio, Londero, Angela, Della Siega, Paola, Givone, Filippo, Fabris, Martina, Biasizzo, Jessica, Tascini, Carlo, Pea, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052551/
https://www.ncbi.nlm.nih.gov/pubmed/33864624
http://dx.doi.org/10.1007/s40262-021-00996-1
_version_ 1783679944478425088
author Cojutti, Pier Giorgio
Londero, Angela
Della Siega, Paola
Givone, Filippo
Fabris, Martina
Biasizzo, Jessica
Tascini, Carlo
Pea, Federico
author_facet Cojutti, Pier Giorgio
Londero, Angela
Della Siega, Paola
Givone, Filippo
Fabris, Martina
Biasizzo, Jessica
Tascini, Carlo
Pea, Federico
author_sort Cojutti, Pier Giorgio
collection PubMed
description
format Online
Article
Text
id pubmed-8052551
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-80525512021-04-19 Authors’ Reply to Cattaneo et al.: “Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin6” Cojutti, Pier Giorgio Londero, Angela Della Siega, Paola Givone, Filippo Fabris, Martina Biasizzo, Jessica Tascini, Carlo Pea, Federico Clin Pharmacokinet Letter to the Editor Springer International Publishing 2021-04-17 2021 /pmc/articles/PMC8052551/ /pubmed/33864624 http://dx.doi.org/10.1007/s40262-021-00996-1 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Letter to the Editor
Cojutti, Pier Giorgio
Londero, Angela
Della Siega, Paola
Givone, Filippo
Fabris, Martina
Biasizzo, Jessica
Tascini, Carlo
Pea, Federico
Authors’ Reply to Cattaneo et al.: “Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin6”
title Authors’ Reply to Cattaneo et al.: “Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin6”
title_full Authors’ Reply to Cattaneo et al.: “Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin6”
title_fullStr Authors’ Reply to Cattaneo et al.: “Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin6”
title_full_unstemmed Authors’ Reply to Cattaneo et al.: “Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin6”
title_short Authors’ Reply to Cattaneo et al.: “Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin6”
title_sort authors’ reply to cattaneo et al.: “comment on: comparative population pharmacokinetics of darunavir in sars-cov-2 patients vs. hiv patients: the role of interleukin6”
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052551/
https://www.ncbi.nlm.nih.gov/pubmed/33864624
http://dx.doi.org/10.1007/s40262-021-00996-1
work_keys_str_mv AT cojuttipiergiorgio authorsreplytocattaneoetalcommentoncomparativepopulationpharmacokineticsofdarunavirinsarscov2patientsvshivpatientstheroleofinterleukin6
AT londeroangela authorsreplytocattaneoetalcommentoncomparativepopulationpharmacokineticsofdarunavirinsarscov2patientsvshivpatientstheroleofinterleukin6
AT dellasiegapaola authorsreplytocattaneoetalcommentoncomparativepopulationpharmacokineticsofdarunavirinsarscov2patientsvshivpatientstheroleofinterleukin6
AT givonefilippo authorsreplytocattaneoetalcommentoncomparativepopulationpharmacokineticsofdarunavirinsarscov2patientsvshivpatientstheroleofinterleukin6
AT fabrismartina authorsreplytocattaneoetalcommentoncomparativepopulationpharmacokineticsofdarunavirinsarscov2patientsvshivpatientstheroleofinterleukin6
AT biasizzojessica authorsreplytocattaneoetalcommentoncomparativepopulationpharmacokineticsofdarunavirinsarscov2patientsvshivpatientstheroleofinterleukin6
AT tascinicarlo authorsreplytocattaneoetalcommentoncomparativepopulationpharmacokineticsofdarunavirinsarscov2patientsvshivpatientstheroleofinterleukin6
AT peafederico authorsreplytocattaneoetalcommentoncomparativepopulationpharmacokineticsofdarunavirinsarscov2patientsvshivpatientstheroleofinterleukin6

Ejemplares similares